Patrick Ott
帕特里克·奥特
MD, PhD
Director, Melanoma Disease Center; Associate Professor of Medicine, Harvard Medical School黑色素瘤疾病中心主任；哈佛医学院医学副教授
👥Biography 个人简介
Patrick Ott is Director of the Melanoma Disease Center at Dana-Farber Cancer Institute and a leading clinical investigator in personalized neoantigen cancer vaccines. He co-led the landmark NeoVax phase 1 clinical trial demonstrating that individualized neoantigen peptide vaccines induce durable neoepitope-specific T cell immunity and clinical responses in melanoma patients.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
NeoVax Phase 1 Clinical Trial — Personalized Neoantigen Peptide Vaccines
Co-led the first-in-human NeoVax phase 1 trial in resected high-risk melanoma patients, demonstrating that individualized neoantigen vaccines induced neoepitope-specific CD4+ and CD8+ T cell responses with long-term immune memory and favorable clinical outcomes.
Long-Term Neoantigen Vaccine Immunity and Combination with PD-1 Blockade
Demonstrated 4-year follow-up data from NeoVax showing persistent neoantigen-specific T cell responses and evidence that patients who relapsed could respond to anti-PD-1 therapy, establishing neoantigen vaccines as combination immunotherapy partners.
Extension of NeoVax to Glioblastoma and Other Tumor Types
Expanded the NeoVax neoantigen vaccine platform to glioblastoma in a phase 1b trial, showing vaccine-induced neoantigen-reactive T cells could traffic to the brain tumor microenvironment, broadening the vaccine's clinical applicability.
Representative Works 代表性著作
An immunogenic personal neoantigen vaccine for patients with melanoma
Nature (2017)
Landmark phase 1 trial demonstrating individualized neoantigen peptide vaccines (NeoVax) induced neoepitope-specific T cell immunity in all treated melanoma patients, with no recurrences in 4 of 6 patients at median 25 months follow-up.
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Nature (2019)
First evidence that personalized neoantigen vaccines can induce tumor-infiltrating neoantigen-reactive T cells in glioblastoma, demonstrating CNS tumor accessibility for vaccine-induced T cell immunity.
Durable neoantigen-specific immune responses and clinical outcomes after personalized cancer vaccine and checkpoint blockade in melanoma
Nature Medicine (2022)
Four-year follow-up of NeoVax trial demonstrating durable neoantigen-specific T cell memory and improved clinical outcomes in melanoma patients following combination with PD-1 blockade.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 帕特里克·奥特 的研究动态
Follow Patrick Ott's research updates
留下邮箱，当我们发布与 Patrick Ott（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment